Literature DB >> 20061820

Immunotherapy for Alzheimer disease.

Gunnar K Gouras1.   

Abstract

Immunotherapy approaches for Alzheimer disease currently are among the leading therapeutic directions for the disease. Active and passive immunotherapy against the beta-amyloid peptides that aggregate and accumulate in the brain of those afflicted by the disease have been shown by numerous groups to reduce plaque pathology and improve behavior in transgenic mouse models of the disease. Several ongoing immunotherapy clinical trials for Alzheimer disease are in progress. The background and ongoing challenges for these immunological approaches for the treatment of Alzheimer disease are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20061820      PMCID: PMC2725424          DOI: 10.4161/mabs.1.2.7829

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  19 in total

1.  Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Authors:  F Bard; C Cannon; R Barbour; R L Burke; D Games; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; I Lieberburg; R Motter; M Nguyen; F Soriano; N Vasquez; K Weiss; B Welch; P Seubert; D Schenk; T Yednock
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Authors:  R B DeMattos; K R Bales; D J Cummins; J C Dodart; S M Paul; D M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 3.  Immunity and acquired alterations in cognition and emotion: lessons from SLE.

Authors:  Betty Diamond; Czeslawa Kowal; Patricio T Huerta; Cynthia Aranow; Meggan Mackay; Lorraine A DeGiorgio; Ji Lee; Antigone Triantafyllopoulou; Joel Cohen-Solal; Bruce T Volpe
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

4.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

Authors:  D Morgan; D M Diamond; P E Gottschall; K E Ugen; C Dickey; J Hardy; K Duff; P Jantzen; G DiCarlo; D Wilcock; K Connor; J Hatcher; C Hope; M Gordon; G W Arendash
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

5.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

6.  Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies.

Authors:  Michal Arbel; Iftach Yacoby; Beka Solomon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-13       Impact factor: 11.205

Review 7.  Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.

Authors:  Gunnar K Gouras; Claudia G Almeida; Reisuke H Takahashi
Journal:  Neurobiol Aging       Date:  2005-10       Impact factor: 4.673

8.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.

Authors:  Josep Dalmau; Amy J Gleichman; Ethan G Hughes; Jeffrey E Rossi; Xiaoyu Peng; Meizan Lai; Scott K Dessain; Myrna R Rosenfeld; Rita Balice-Gordon; David R Lynch
Journal:  Lancet Neurol       Date:  2008-10-11       Impact factor: 44.182

9.  Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.

Authors:  Salvatore Oddo; Lauren Billings; J Patrick Kesslak; David H Cribbs; Frank M LaFerla
Journal:  Neuron       Date:  2004-08-05       Impact factor: 17.173

10.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

Authors:  Christoph Hock; Uwe Konietzko; Johannes R Streffer; Jay Tracy; Andri Signorell; Britta Müller-Tillmanns; Ulrike Lemke; Katharina Henke; Eva Moritz; Esmeralda Garcia; M Axel Wollmer; Daniel Umbricht; Dominique J F de Quervain; Marc Hofmann; Alessia Maddalena; Andreas Papassotiropoulos; Roger M Nitsch
Journal:  Neuron       Date:  2003-05-22       Impact factor: 17.173

View more
  1 in total

1.  Elongation of the C-terminal domain of an anti-amyloid β single-chain variable fragment increases its thermodynamic stability and decreases its aggregation tendency.

Authors:  Geovanny Rivera-Hernández; Marta Marin-Argany; Bernat Blasco-Moreno; Jaume Bonet; Baldo Oliva; Sandra Villegas
Journal:  MAbs       Date:  2013-06-19       Impact factor: 5.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.